Assertion: albumin | /r/HasProperty | human
Facets:
Source sentences:
text: The following adverse reactions have been identified during post-approval use of ALBUMIN (HUMAN) (any strength).
text: ALBUMIN (HUMAN)
text: Albumin (Human)
text: Indications and Usage for Albumin (Human)
text: Albumin (Human) 20% is indicated in the emergency treatment of hypovolemia with or without shock.
text: When albumin deficit is the result of excessive protein loss, the effect of administration of Albumin (Human)
text: Albumin (Human)
text: Albumin (Human) 20% may be used as a plasma expander in fluid management relating to severe forms of ovarian hyperstimulation syndrome (OHSS).
text: Albumin (Human) 20% infusions may be indicated in conjunction with diuretics to correct the fluid volume overload associated with ARDS.
text: Albumin (Human)
text: Albumin (Human) 20% is indicated in the treatment of hyperbilirubinemia.
text: Albumin (Human) 20% Dosage and Administration
text: The daily dose should not exceed 2 g of Albumin (Human)
text: Hemodilution may follow administration of Albumin (Human) 20%.
text: In adults, intravenous infusion of 50 to 75 g of Albumin (Human)
text: After 24 hours, Albumin (Human) 20% may be added at an initial dose of 25 g with the dose adjusted thereafter to maintain a plasma protein concentration of 2.5 g per 100 mL or a serum protein concentration of 5.2 g/100 mL.
text: In adults, intravenous infusion of 8 g of Albumin (Human)
text: In adults, as a guideline, doses of 50 – 100 g of Albumin (Human)
text: In adults, a dose of 25 g of Albumin (Human)
text: In adults, a dose of 25 g of Albumin (Human)
text: In newborns, Albumin (Human) 20% may be administered prior to or during exchange transfusion at a dose of 1 g per kilogram body weight.
text: Do not use solutions of Albumin (Human) 20% which are cloudy or have deposits.
text: Albumin (Human) 20% is supplied in
text: 20-25% Albumin (Human) is relatively low in electrolytes compared to the 4-5% Albumin (Human) solutions.
text: If Albumin (Human) 20% is to be administered, monitor hemodynamic performance regularly; this may include:
text: Albumin (Human) 20% must not be diluted with sterile water for injection as this may cause hemolysis in recipients.
text: No cases of transmission of viral diseases or CJD have been identified for Albumin (Human) 20%.
text: Adverse reactions for Albumin (Human) 20% normally resolve when the infusion rate is slowed down or the infusion is stopped.
text: No clinical studies were done using Albumin (Human) 20%
text: Pregnancy Category C. Animal reproduction studies have not been performed with Albumin (Human) 20%.
text: It is also not known whether Albumin (Human) 20% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.
text: Albumin (Human)
text: It is also not known whether Albumin (Human) 20% can cause fetal harm when administered to a woman during labor or delivery of if it will affect reproductive capacity.
text: Albumin (Human)
text: Albumin (Human)
text: Because many drugs are excreted in human milk, caution should be exercised when Albumin (Human) 20% is administered to a lactating woman.
text: Data on the use of Albumin (Human) 20% in children including premature babies are very limited.
text: Albumin (Human)
text: Albumin (Human)
text: All units of human plasma used in the manufacture of Albumin (Human) 20% are provided by FDA approved blood establishments only.
text: The Albumin (Human) 20% manufacturing process provides a significant viral reduction in in vitro studies (table 2).
text: In vitro reduction factor during Albumin (Human) 20% manufacturing
text: Albumin (Human)
text: The composition of Albumin (Human) 20% is as follows:
text: Albumin (Human) 20% contains no preservatives and components used in its packaging are latex-free.
text: Albumin (Human) 20% - Clinical Pharmacology
text: No pharmacokinetic or pharmacodynamic studies with Albumin (Human) 20% have been conducted.
text: The colloid osmotic effect of Albumin (Human) 20% and 25% is approximately 5 times the volume administered.
text: No non-clinical toxicology studies with Albumin (Human) 20% have been conducted.
text: No clinical studies with Albumin (Human) 20% have been conducted.
text: Albumin (Human) 20% is supplied in 10 g in 50 mL or 20 g in 100 mL single use bottles.
text: Albumin (Human) 20% may be stored for 36 months at +2°C to + 25°C (36°F to 77°F) from the date of manufacture.
text: Inform patients being treated with Albumin (Human) 20% about the potential risks and benefits with its use [see Adverse Reactions (6)].
text: Inform patients that Albumin (Human) 20% is a derivative of human plasma and may contain infectious agents that cause disease (e.g., viruses, and theoretically, CJD agent).
text: Inform patients that the risk that Albumin (Human) 20% may transmit an infections agent has been reduced by screening plasma donors for prior exposure for certain viruses, by testing the donated plasma for certain virus infections and by inactivating and/or removing certain viruses during manufacturing [see Warnings and Precautions
text: Albumin (Human)
text: Albumin (Human)
text: Albumin (Human) is a concentrate of plasma proteins from human blood.
text: * you are allergic to any ingredient in Albumin (Human)